Compare iShares China Large-Cap ETF (FXI) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares China Large-Cap ETF trades at $34.25 (market cap $3.86B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: iShares China Large-Cap ETF is far larger — about 34.4× Inovio Pharmaceuticals Inc's market cap, and iShares China Large-Cap ETF is more actively traded (16,323,837 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FXI | INO | |
|---|---|---|
Market Cap | $3.86B | $112.19M |
Volume | 16,323,837 | 3,201,278 |
52-Week High | $41.08 | $2.60 |
52-Week Low | $31.59 | $0.66 |
Typical Hold Time | 150 Days | 43 Days |
Sector | — | Health |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $33.45 with minimal daily movement (+0.09%), reflecting cautious sentiment amid mixed technical signals. The ETF shows bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. Recent news highlights China's economic challenges including industrial overcapacity and trade tensions, while corporate profits showed strong growth in Q2 2026. The ETF trades at a significant discount to U.S. equities with a P/E ratio approximately half that of the S&P 500.
FXI offers value exposure to Chinese large-caps but faces headwinds from geopolitical risks and economic rebalancing. The Trump-Xi summit provided limited progress on trade tensions, while China's export controls and domestic stimulus measures create uncertainty. Institutional sentiment remains divided between the valuation opportunity and persistent political risks.
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
